Back pain prevention in multiple myeloma using an external spinal brace
| ISRCTN | ISRCTN11368725 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN11368725 |
| ClinicalTrials.gov (NCT) | NCT02898064 |
| Protocol serial number | 1017 |
| Sponsor | University Hospitals of North Midlands NHS Trust |
| Funder | National Institute for Health Research |
- Submission date
- 12/06/2017
- Registration date
- 05/07/2017
- Last edited
- 10/05/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Signs and Symptoms
Plain English summary of protocol
Background and study aims
Myeloma is a blood cancer that affects several bones, mostly the spine. Around one person in 120-150 is at risk of developing myeloma. Current treatment can control the cancer. However, it does not offer a cure and has little effect on preventing back pain, disability, or spinal deformity – which may need difficult spinal surgery. An external spinal brace during treatment may be able to reduce back pain intensity, help prevent disability, minimise the risk of spinal deformity, and reduce the need for surgery. Managing back pain in myeloma with a brace has not been tested and is not routine practice in other centres in the UK. Therefore, the aim of this study is to find out whether it is possible to run a full study of the brace in multiple centres, which would assess whether using a brace minimises back pain and disability compared to standard medical treatment alone.
Who can participate?
Patients aged over 18 with myeloma-related back pain
What does the study involve?
Participants are randomly allocated to receive either standard medical treatment (chemotherapy, pain-killing medication) alone or a brace with standard medical treatment. Participants are regularly assessed at research clinics to determine the number of patients required for the full study. Information is collected to inform a list of requirements a centre needs to have in place to run the full study. The total duration of treatment and follow up is 3 months, and a subset of 20 participants is asked to complete a questionnaire at the end of the 3-month period.
What are the possible benefits and risks of participating?
Patients with MM are surviving longer, but are often left with a disability due to chronic back pain. The full study will determine whether using a simple low-cost brace can decrease back pain in these patients and improve their disability, thus potentially improving the quality of life of these patients and reducing the cost to the NHS. This study will find out whether the full study is possible and, if so, inform its design.
Where is the study run from?
1. University Hospitals of North Midlands NHS Trust (UK)
2. Royal Wolverhampton NHS Trust (UK)
When is the study starting and how long is it expected to run for?
June 2016 to May 2018
Who is funding the study?
National Institute for Health Research (UK)
Who is the main contact?
Mr Sandeep Konduru
Contact information
Public
University Hospitals of North Midlands NHS Trust
Royal Stoke University Hospital
Newcastle Road
Stoke on Trent
ST4 6QG
United Kingdom
 ORCID ID |
0000-0001-6884-5737 |
|---|
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled multi-centre feasibility trial with two parallel groups |
| Secondary study design | Randomised controlled trial |
| Participant information sheet | ISRCTN11368725_PIS_26Aug16.docx |
| Scientific title | Back pain prevention in multiple myeloma using an external spinal brace (MAPP) - a feasibility study |
| Study acronym | MAPP |
| Study objectives | Is it feasible to use an external spinal brace to decrease back pain and spine related disability in patients suffering from back pain due to multiple myeloma? |
| Ethics approval(s) | East Midlands - Leicester South Research Ethics Committee, 27/05/2016, ref: 16/EM/0166 |
| Health condition(s) or problem(s) studied | Back pain in multiple myeloma |
| Intervention | Participants will be randomly assigned to either control or intervention groups with 1:1 allocation via a computerised random number generator using permuted blocks of random sizes. The randomisation procedure will be conducted by an independent statistician at Keele University and will be stratified by site; block sizes will not be disclosed to ensure concealment. Sealed opaque envelopes containing group allocations will be available at each centre. These will be opened by the research nurse following collection of baseline measurements. Patients will be randomly allocated to receive either standard medical treatment alone or standard medical treatment plus an external back brace. (Standard medical treatment consists of chemotherapy, radiotherapy, pain killing medication). Patients will be regularly evaluated in research clinics to determine the number of patients required for the full trial. Information will be collected to inform a list of requirements a centre needs to have in place to run an RCT. Total duration of treatment and follow up will be three months for all treatment arms with a subset of 20 participants being asked to take part in a qualitative questionnaire at the end of the 3-month period. |
| Intervention type | Device |
| Phase | |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure(s) |
1. Time from diagnosis to brace fitting for patients randomised to the intervention group. Dates to be collected by the research team - aim to complete trial recruitment process, i.e. consent to fitting of back brace, within 4 weeks |
| Key secondary outcome measure(s) |
1. The number of new MM cases at each centre and the number eligible for the study during 1 recruitment year, measured at screening |
| Completion date | 31/05/2018 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 80 |
| Key inclusion criteria | 1. Adults with MM 2. Myeloma infiltration in the spine confirmed by radiological evidence 3. MM-related back pain 4. Can attend for the whole follow-up period 5. Aged >18 years |
| Key exclusion criteria | 1. Presenting with cord compression and neurological deficit requiring urgent decompression and intervention 2. Chronic pain syndrome 3. Language barrier that cannot be overcome using translation services 4. Unwilling or unable to give informed consent 5. Painful vertebral compression fractures (VCFs) at the lumbosacral junction (L4 to Sacrum) where application of brace is not possible 6. Not suitable for treatment with a brace e.g. pregnancy |
| Date of first enrolment | 03/01/2017 |
| Date of final enrolment | 28/02/2018 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centres
United Kingdom
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Other |
| IPD sharing plan | The datasets generated and/or analysed during the current study will be included in the subsequent results publication. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No | ||
| Participant information sheet | 26/08/2016 | 05/07/2017 | No | Yes | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Additional files
- ISRCTN11368725_PIS_26Aug16.docx
- Uploaded 05/07/2017
Editorial Notes
10/05/2019: No publications found. Verifying results with principal investigator.
